The Wegovy Pill (Oral Semaglutide): What to Know

Oral semaglutide (the Wegovy pill) is the first GLP-1 medication approved for weight loss in a tablet form. Approved by the FDA in December 2025 and launched in January 2026, it uses the same active molecule as injectable Wegovy but is taken once daily. Here's what that means in practice.

What is oral semaglutide and how does it work?

Semaglutide is a GLP-1 receptor agonist — it mimics the hormone GLP-1, which the body naturally releases after eating. By activating GLP-1 receptors, it slows gastric emptying, reduces appetite, and helps regulate blood sugar. This is the same mechanism behind injectable Wegovy and Ozempic.

Oral semaglutide adds an absorption enhancer (SNAC — sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) that allows semaglutide to cross the stomach lining and enter the bloodstream when taken as a tablet. Without this, semaglutide would be broken down in the digestive tract before it could act.

The FDA approved oral semaglutide for weight loss in December 2025, and it became available in January 2026 — also indicated for cardiovascular risk reduction in adults with obesity or overweight.

How does the Wegovy pill differ from the injection?

The active molecule is the same, but the delivery and dosing differ in important ways:

• Dosing frequency: The pill is taken daily; the injection is weekly.
• Absorption requirements: The pill must be taken on an empty stomach, with a small amount of plain water (no more than 120 ml), and you must wait at least 30 minutes before eating, drinking anything else, or taking other medicines. Missing this window reduces absorption significantly.
• Needle: None required with the pill — this is a meaningful advantage for many people with needle aversion.
• Consistency: Daily dosing means more daily decision-making than a once-weekly injection.

The consistency required with oral dosing is real. Taking it correctly — same time, fasted, small amount of water — matters for how much of the dose reaches your bloodstream.

Who is it approved for?

The FDA approval covers adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity. It is also indicated for cardiovascular risk reduction in qualifying adults.

Approval criteria and prescribing practice can vary by country and healthcare system. Talk to your clinician about whether you qualify and what the access pathway looks like where you are.

What should I discuss with my clinician before starting?

Some questions worth raising:

• Is the pill or injection format more appropriate for my situation?
• What dose will I start on, and what does the titration schedule look like?
• Are there any medications I take that could interact with the absorption window requirements?
• What protein and supplement support should I have in place to protect muscle during rapid weight loss?
• What monitoring will we do, and how often?

Both the pill and the injection produce meaningful calorie restriction — which puts muscle at risk. Regardless of which format you're on, protein targets (your bodyweight in kg × 1.2–1.6 g), resistance training 2–3 times a week, and evidence-dosed supplements like creatine and magnesium are worth having in place from the start.